Medarex and Lonza Sign Collaboration Agreement for the Supply of Antibody-Based Products

Agreement Includes Manufacture of Antibodies and Antibody Drug Conjugates

10-Jul-2009 - Switzerland

Lonza and Medarex, Inc. announced that they have signed an agreement giving Medarex the option to work with Lonza as a collaboration partner to provide manufacturing services in support of the development and commercialization of Medarex’s pipeline of therapeutic proteins and antibody drug conjugates (ADCs). As part of the agreement, Lonza may provide process development services for certain Medarex programs and may reserve manufacturing capacity for Medarex antibody and antibody drug conjugate programs at Lonza’s biopharmaceutical facilities around the world. Further details of the agreement were not disclosed.

Medarex’s biologics portfolio is focused on treating oncology and immunology therapeutic indications with ten antibody programs in Phase 3 to Phase 1 clinical development.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous